Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 193

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 193
---
 coronavirus (COVID-19), influenza and other highly communicable diseases or viruses could adversely impact our operations
and disrupt our ongoing or planned research and development activities. We cannot presently predict the scope and severity of any potential
future business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including the suppliers, clinical
trial sites, regulators and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions,
our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted.

We are exposed to risks related to currency
exchange rates.

We conduct a significant portion
of our operations outside of the United States. Because our financial statements are presented in U.S. dollars, changes in currency exchange
rates have had and could have in the future a significant effect on our operating results when our operating results are translated into
U.S. dollars.

Our employees,
principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance
with regulatory standards and requirements and insider trading, which could cause significant liability for us and harm our reputation.

We are exposed to the risk
of fraud or other misconduct by our employees, principal investigators, consultants and collaborators, including intentional failures
to comply with FDA or Office of Inspector General regulations or similar regulations of comparable non-U.S. regulatory authorities, provide
accurate information to the FDA or comparable non-U.S. regulatory authorities, comply with manufacturing standards we have established,
comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced
by comparable non-U.S. regulatory authorities, report financial information or data accurately or disclose unauthorized activities to
us. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could
result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws,
standards or regulations. Such actions could have a significant impact on our business and results of operations, including the imposition
of significant fines or other sanctions.

47

A cybersecurity incident and other technological
disruptions could negatively affect our business and our relationships with customers.

We use technology in substantially